B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SIGMA

MOLECULAR TARGET

Sigma non-opioid intracellular receptor 1 (human)

UniProt: Q9972015 compounds

SIGMA (Sigma non-opioid intracellular receptor 1 (human)) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SIGMA

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Progesterone1.102
2Quetiapine Fumarate1.102
3Sertraline1.102
4Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent1.102
5Astemizole Antihistamine drug now withdrawn from1.102
6Buspirone1.102
7Cinnarizine1.102
8Dimenhydrinate1.102
9Flunarizine Flunarizine is1.102
10Labetalol1.102
11Levobunolol1.102
12Promethazine1.102
13Propranolol1.102
14Trazodone1.102
15Econazole0.691

About SIGMA as a Drug Target

SIGMA (Sigma non-opioid intracellular receptor 1 (human)) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented SIGMA interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SIGMA inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.